Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationInactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents
Beranek, D. T. (1990) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/0027-5107(90)90173-2 · Cited by 899
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878 · cited 15×
“Fas receptor (CD95/Apo1) was inhibited by adding 1 mg/ml anti-Fas neutralizing antibody (ZB4) (Biozol Diagnostica Vertrieb GmbH, Eching, Germany) 72 h after MNNG treatment and then every 24 h till samples were harvested.”
BackgroundInfluentialMGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Renart, J., Reiser, J., & Stark, G. R. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.7.3116 · Cited by 728
Cited by
DNA damage-induced cell death by apoptosis
Roos, W. P., & Kaina, B. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.007 · Cited by 1,500
Self-citationDNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
Self-citationDNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Self-citationHegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Self-citationKaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Self-citationA highlight on Sonic hedgehog pathway
Carballo, G. B., Honorato, J. R., de Lopes, G. P. F., & Spohr, T. C. L. D. S. E. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0220-7 · Cited by 460
Pyrko, P., Schönthal, A. H., Hofman, F. M., Chen, T. C., & Lee, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0625 · Cited by 450
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Beier, D., Schulz, J. B., & Beier, C. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-128 · Cited by 312
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
Knizhnik, A. V., Roos, W. P., Nikolova, T., Quiros, S., Tomaszowski, K.-H., Christmann, M., & Kaina, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055665 · Cited by 273
Self-citationMolecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
Zhang, Z., Yin, J., Lu, C., Wei, Y., Zeng, A., & You, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1139-6 · Cited by 265
Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets
Miranda-Gonçalves, V., Honavar, M., Pinheiro, C., Martinho, O., Pires, M. M., Pinheiro, C., Cordeiro, M., Bebiano, G., Costa, P., Palmeirim, I., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos298 · Cited by 252
Lefranc, F., Facchini, V., & Kiss, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1395 · Cited by 237
How DNA lesions are turned into powerful killing structures: Insights from UV-induced apoptosis
Batista, L. F. Z., Kaina, B., Meneghini, R., & Menck, C. F. M. (2009) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.09.001 · Cited by 234
Self-citationBerdelle, N., Nikolova, T., Quiros, S., Efferth, T., & Kaina, B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0534 · Cited by 181
Self-citationExtracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells
Mierke, C. T. (2024) · Cells · doi:10.3390/cells13010096 · Cited by 146
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Paolillo, M., Boselli, C., & Schinelli, S. (2018) · Brain Sciences · doi:10.3390/brainsci8010015 · Cited by 135
“MGMT is an enzyme involved in DNA repair processes that counteract mutagenesis from alkylating agents [24,25].”
BackgroundYoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
Wiewrodt, D., Nagel, G., Dreimüller, N., Hundsberger, T., Perneczky, A., & Kaina, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23219 · Cited by 114
“Furthermore, p53 determines the efficiency of execution of apoptosis in glioma cells upon TMZ or CNU treatment.(10,52) Therefore, we determined the p53 status of the tumors, which was performed by means of immunohistochemistry,(15) and set it in relation to MGMT and therapeutic response.”
BackgroundMethodResultSelf-citationKrumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2680 · Cited by 91
“Preparation of protein extracts and Western blot analysis Preparation of whole cell (24) and nuclear (25) protein extracts were described previously.”
Self-citationMa, L., Barker, J., Zhou, C., Li, W., Zhang, J., Lin, B., Foltz, G., Küblbeck, J., & Honkakoski, P. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.054 · Cited by 83
Barckhausen, C., Roos, W. P., Naumann, S. C., & Kaina, B. (2014) · Oncogene · doi:10.1038/onc.2013.141 · Cited by 77
Self-citationStojcheva, N., Schechtmann, G., Sass, S., Roth, P., Florea, A.-M., Stefanski, A., Stühler, K., Wolter, M., Müller, N. S., Theis, F. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7346 · Cited by 50
Self-citationLan, Y., Lou, J., Hu, J., Yu, Z., Lyu, W., & Zhang, B. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0164 · Cited by 46
Metadata
- Authors
- Roos, W. P., Batista, L. F. Z., Naumann, S. C., Wick, W., Weller, M., Menck, C. F. M., & Kaina, B.
- Venue
- Oncogene
- Published
- 2006-07-03
- Volume
- 26
- Issue
- 2
- Pages
- 186-197
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2089482729
- Cited by
- 495
- References
- 49
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.